Future of MCL Treatment May Lie in Combinations, CAR T-Cell Therapy
Robert Dean, MD, discusses the promise for new therapies in mantle cell lymphoma.
Tepotinib Plus Gefitinib Improves PFS in MET+ EGFR-Mutant NSCLC
The combination of tepotinib plus gefitinib improved progression-free survival and overall response versus chemotherapy in patients with MET mutated EGFR-positive non–small cell lung cancer resistant to prior EGFR TKI therapy.
CAR T-Cell Therapy Brings Hope to Relapsed/Refractory Myeloma
Eric Smith, MD, PhD, discusses the development of novel CAR T-cell therapies for patients with multiple myeloma.
Asymptomatic, Young Patients With MCL May Avoid Active Treatment
Frontline therapy may be able to be avoided in asymptomatic, young, fit patients with mantle cell lymphoma.
Role of CAR T-Cell Therapy in Pediatric ALL Continues to Be Refined
While clinical trial findings with chimeric antigen receptor (CAR) T-cell therapy have impacted the landscape of pediatric acute lymphoblastic leukemia, additional CAR T-cell products continue to be investigated.
Deferred Treatment Beneficial in Some Patients With MCL
Jonathon B. Cohen, MD, discusses the potential benefit of offering deferred therapy to asymptomatic patients with mantle cell lymphoma.
Maintenance Rituximab Linked to Improved Outcomes in MCL
Talal Hilal, MB, BCh, discusses the findings of a meta-analysis of rituximab maintenance for patients with mantle cell lymphoma (MCL), and the approach to maintenance therapy in patients with MCL.
Update Sustains Liso-Cel as Strong Contender in CAR T-Cell Space
The CD19-directed chimeric antigen receptor T-cell therapy lisocabtagene maraleucel (JCAR017; liso-cel) is showing promising response rates in patients with high-risk diffuse large B-cell lymphoma.
CAR T-Cell Therapy Explored in Mantle Cell Lymphoma
The CD19-targeted CAR T-cell product axicabtagene ciloleucel (axi-cel; Yescarta) is currently being investigated in patients with relapsed/refractory MCL in the ongoing ZUMA-2 trial.
CAR T-Cell Therapy, Checkpoint Inhibitors Making Waves Across Hematologic Malignancies
Anas Younes, MD, discusses the current and future state of CAR T-cell therapies and immune checkpoint inhibitors in the landscape of hematologic malignancies.
Expert Explains Shifting Myeloma Paradigm
Keith Stewart, MB, ChB, discusses the role of stem cell transplant, minimal residual disease testing, and maintenance therapy in the treatment of patients with multiple myeloma.
Landgren Explains Evolving Myeloma Landscape
C. Ola Landgren, MD, PhD, shares his insight on CAR T-cell therapy, sequencing, and triplet and quadruplet regimens in myeloma.
Novel Agents, CAR T Cells Reinvigorate ALL Landscape
Jae H. Park, MD, discusses the impact of agents such as blinatumomab, inotuzumab ozogamicin, and tisagenlecleucel on the treatment of acute lymphoblastic leukemia.
Goldberg Gives Expert Insight on EGFR-TKI Resistant NSCLC
Sarah B. Goldberg, MD, discusses testing for and treating resistance to EGFR TKI therapy in non-small cell lung cancer.
CAR T-Cell Therapy Shows Promise in Relapsed/Refractory Myeloma
Jesus Berdeja, MD, discusses ongoing research with bb2121 in patients with relapsed/refractory myeloma.
Considerations for CAR T-Cell Therapy in NHL
Babis Andreadis, MD, discusses the successes seen with CAR T-cell development in the past year and the use of CAR T-cell therapy in patients with NHL.
Expert Highlights Advances in CAR T-Cell Therapy
Noelle Frey, MD, discusses the FDA approvals of CAR T-cell therapies, as well as the bright future of the treatment.
Novel Agents, Combos Excite in Multiple Myeloma
Dan T. Vogl, MD, highlights the potential with CAR T-cell therapy in the multiple myeloma paradigm.
CAR T-Cell Therapy Approval Starts New Path in Childhood Leukemia
Sarah K. Tasian, MD, discusses the success of CAR T-cell therapy, as well as novel agents and immunotherapies that appear promising in the treatment of children with leukemia.
Acalabrutinib MCL Approval Raises Sequencing Questions
Owen A. O'Connor, MD, PhD, discussed the utilization of acalabrutinib (Calquence), how it sequences with other approved therapies, and the promise for chimeric antigen receptor T-cell therapy in mantle cell lymphoma.
Expert Highlights CAR T-Cell Breakthroughs
David G. Maloney, MD, PhD, discusses the progress made with CAR T cells, as well as the challenges that still exist in the use of this therapy.
CAR T-Cell Approvals Leading Landscape of Hematologic Cancers
Andre Goy, MD, discusses the recent success with CAR T-cell therapy, and what is on the horizon for this therapeutic option across hematologic malignancies.
Kumar Discusses Latest Developments in Myeloma
Shaji Kumar, MD, discusses his ixazomib maintenance trial, the latest FDA activity in myeloma, and the potential of chimeric antigen receptor (CAR) T-cell therapy in the field of myeloma.
Cohen Discusses Immunotherapy Combos, CAR T-Cell Therapy in HNSCC
Ezra Cohen, MD, discusses anti–PD-1/PD-L1 combination regimens in HNSCC, the potential for CAR T-cell therapy, and remaining challenges with immunotherapy in the field.
Expert Discusses CD19 CAR T-Cell Therapy in B-Cell ALL
Eric Smith, MD, PhD, discusses the response to CD19 CAR T-cell therapy in B-cell ALL.
Expert Summarizes State of CAR T-Cell Therapy in Hematologic Malignancies
Alfred L. Garfall, MD, discusses the latest developments with CAR T-cell therapy in hematologic malignancies
CRISPR Builds More Powerful CAR T Cells
Michel Sadelain, MD, PhD, discusses CRISPR and its effect on CAR T cells.
2 Commerce Drive Cranbury, NJ 08512